Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX17725 in Netherton syndrome
NL-OMON59469Phase 2Recruiting
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Mar 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of BCX17725 in Netherton syndrome (NS), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoints: Change from baseline in Ichthyosis Area and Severity Index, Incidence of treatment-emergent adverse events and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
BCX17725
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on NL-OMON59469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59469.